Moleculin Biotech (MBRX) Other Accumulated Expenses (2019 - 2020)
Moleculin Biotech (MBRX) posted quarterly Other Accumulated Expenses of $84000.0 for Q4 2020, down 48.78% year-over-year from $164000.0 in Q1 2020, and up 50.0% quarter-over-quarter from $56000.0 in Q3 2020.
Moleculin Biotech (MBRX) Other Accumulated Expenses (2019 - 2020) Analysis & Trends
Moleculin Biotech's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $84000.0 for Q4 2020.
- In Q4 2020, Other Accumulated Expenses fell 48.78% year-over-year to $84000.0; the TTM figure through Dec 2020 stood at $84000.0 (down 48.78% YoY), while the FY2020 annual figure was $84000.0, down 48.78% from the prior year.
- Other Accumulated Expenses for Q4 2020 stood at $84000.0, up from $56000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $164000.0 in Q4 2019, with the low at $56000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 84,000.00 |
| Sep 30, 2020 | 56,000.00 |
| Dec 31, 2019 | 164,000.00 |